Alkermes (ALKS) Non-Current Deferred Tax Liability (2011 - 2026)

Alkermes (ALKS) reported Non-Current Deferred Tax Liability of $181.9 million for Q1 2026, up 112893.79% quarter-over-quarter from $161000.0 in Q1 2016.

Alkermes (ALKS) Non-Current Deferred Tax Liability (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $181.9 million in Q1 2026.

  • Non-Current Deferred Tax Liability for Q1 2026 came in at $181.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $181.9 million (changed N/A YoY), and the FY2015 annual result was $470000.0, down 97.52% from the prior year.
  • Non-Current Deferred Tax Liability grew to $181.9 million in Q1 2026 per ALKS's latest filing, from $161000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $181.9 million in Q1 2026 and troughed at $181.9 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 181.92 Mn
Mar 31, 2026 181.92 Mn
Mar 31, 2016 161,000.00
Mar 31, 2016 161,000.00
Dec 31, 2015 470,000.00
Dec 31, 2015 470,000.00
Sep 30, 2015 6.50 Mn
Sep 30, 2015 6.50 Mn
Jun 30, 2015 12.75 Mn
Jun 30, 2015 12.75 Mn
Mar 31, 2015 16.79 Mn
Mar 31, 2015 16.79 Mn
Dec 31, 2014 18.92 Mn
Dec 31, 2014 18.92 Mn
Sep 30, 2014 21.26 Mn
Sep 30, 2014 21.26 Mn
Jun 30, 2014 26.12 Mn
Jun 30, 2014 26.12 Mn
Mar 31, 2014 25.06 Mn
Mar 31, 2014 25.06 Mn